Shanghai Green new Yi Sheng Pharmaceutical industry today to land

Shanghai Green New (002565) the listing of 26.8 million shares, the shares issued price of 31.20 yuan/share, corresponding to the P/E ratio of 41.22 times times. The company currently has a vacuum aluminized paper capacity of 30,000 tons, 2009 the national market share of 8.14%, is the leading segment of the field. The issue of fund-raising will be to the annual output of 40,000 tons of new eco-packaging materials project and Research and Development Center project, the total investment of 477 million yuan. Company's products are mainly used in tobacco, alcohol and cosmetics, such as consumer goods packaging. Despite the strong control of tobacco production, China's production has remained steady growth in recent years, and liquor products such as market demand for rapid growth. With the improvement of China's environmental standards, the high pollution of packaging materials will gradually be eliminated by the market, vacuum aluminized paper, such as non-toxic, non-polluting, biodegradable green packaging materials in the future development of a broad market space.　　The stock market is expected to be positioned at about 33 yuan.　　Yi Sheng Pharmaceutical (002566) The listing of 22.08 million shares, the shares issued price of 39.90 yuan/share, corresponding to the P/E ratio of 52.5 times times. The company is mainly engaged in research and development of proprietary Chinese medicine, production and sales, the main products include Shengmai injection, vibration source capsules, Heart Yue capsules, qingkailing injection, Guangxi-attached Rehmannia capsules. Vibration source and Heart Yue is the company's exclusive varieties, but also the key to the growth of the company. The issue of fund-raising will be invested in the following three projects: annual expansion of 200 million capsules production line construction project, expansion of 100 million injection production line construction projects, the expansion of provincial Research and Development Center project, the total investment of 276 million yuan. Companies around the development of cardiovascular drugs, with the upstream ginseng resources, clinical pharmacology research is gradually deepening, management to produce mostly, research and development, production links and products have strong competitiveness. The stock market is expected to be positioned at about 43 yuan. (Jinge)